Skip to main content
Official Website of Stem Cell Mexico – Since 2002
Stem Cell Therapy Mexico

Does stem cell therapy cure congestive heart failure?

No. Stem cell therapy does not cure congestive heart failure (CHF), and no stem cell product has been approved by the FDA or the European Medicines Agency to treat it.

Free Consultation
Heart location on a neutral human figure

Heart failure is a chronic condition that is managed over a lifetime with medications, devices, lifestyle measures and, in advanced cases, procedures such as heart transplantation. Research on cell therapy has produced mixed results: a Cochrane review found lower long-term mortality with cell therapy; the largest trial, DREAM-HF, did not meet its main goal; and a randomized trial of intravenous (IV) umbilical cord mesenchymal stem cells (MSCs) reported improvements in ejection fraction and quality of life. At Stem Cell Mexico, CHF protocols use only allogeneic MSCs from Wharton's jelly of the umbilical cord, given by IV infusion as a complement to guideline-based cardiology care. Some patients report better energy and exercise tolerance, and results vary between patients.

This guide explains why heart failure cannot be cured with cell therapy, what it may realistically offer and why standard care remains essential.

Why heart failure is a chronic condition

Heart failure develops when the heart muscle is weakened or stiffened by an underlying cause, such as:

  • Coronary artery disease and heart attacks, which leave scarred, non-contracting areas of muscle.
  • High blood pressure, which thickens and stiffens the heart over years.
  • Cardiomyopathies, including genetic, viral, alcohol-related and chemotherapy-related forms.
  • Valve disease and arrhythmias.
  • Diabetes, obesity, kidney disease and sleep apnea, which strain the heart.

Once the heart muscle is damaged, the body responds with hormonal and structural changes, known as remodeling, that initially compensate but over time worsen heart function. Heart muscle cells (cardiomyocytes) have very limited ability to regenerate in adults. Scar tissue left by a heart attack does not turn back into contracting muscle.

For this reason, heart failure is treated as a chronic disease. Even when symptoms improve dramatically with treatment, the underlying vulnerability remains and must be managed.

What "cure" would require, and why cell therapy does not achieve it

To cure heart failure, a treatment would need to replace lost heart muscle, remove scar tissue, restore normal heart structure and stop the processes that drive progression. Early in cell therapy research, scientists hoped that stem cells would turn into new heart muscle. Years of studies have shown that this does not happen to a meaningful degree with MSCs or bone marrow cells. Instead, the cells appear to act through paracrine signaling, releasing factors that may:

  • Reduce inflammation, which contributes to heart failure progression.
  • Limit fibrosis (scarring).
  • Support small blood vessel formation.
  • Improve the function of surviving heart cells.

These effects may help some patients feel or function better, but they do not rebuild the heart. After IV infusion, a large share of MSCs is temporarily trapped in the lungs, and benefits are believed to come from systemic signaling rather than from cells settling in the heart.

What the evidence shows

Cochrane systematic review

A Cochrane review of 38 randomized trials with about 1,900 participants, mostly using bone-marrow-derived cells, found that cell therapy was associated with lower long-term mortality and fewer non-fatal heart attacks and arrhythmias, but no improvement in heart function on MRI and no reduction in heart failure hospitalizations.

DREAM-HF

The largest trial to date, published in the Journal of the American College of Cardiology, injected allogeneic mesenchymal precursor cells directly into the heart muscle of 565 patients with chronic heart failure with reduced ejection fraction. It did not reduce its primary endpoint, recurrent heart failure hospitalizations. Secondary analyses suggested fewer heart attacks and strokes, findings that are guiding new research.

RIMECARD

A small randomized trial published in Circulation Research gave IV umbilical cord MSCs or placebo to 30 patients with stable heart failure with reduced ejection fraction. At 12 months, ejection fraction improved by about 7 percentage points in the treated group versus about 2 points with placebo, with better functional class and quality of life, and no differences in mortality, hospitalizations or adverse events.

Safety

Meta-analyses of IV MSC trials, including a 2026 analysis focused on umbilical-cord-derived cells, show temporary fever as the most consistent side effect, without an increase in serious infection, thrombosis, cancer or death in controlled trials. No treatment is free of risk, and heart failure patients require careful management of fluids and blood pressure.

Types of heart failure and why they matter

Heart failure is classified by ejection fraction (EF), the percentage of blood the left ventricle pumps with each beat:

  • Reduced ejection fraction (HFrEF): EF of 40% or less. Most cell therapy trials, including RIMECARD and DREAM-HF, studied this group.
  • Mildly reduced ejection fraction (HFmrEF): EF between 41% and 49%.
  • Preserved ejection fraction (HFpEF): EF of 50% or more, with a stiff heart that fills poorly. Less cell therapy research has focused on this type.

Severity is also described by NYHA functional class, from class I (no symptoms with ordinary activity) to class IV (symptoms at rest). People in class IV, or with frequent hospitalizations, have the least reserve and the highest risk with any procedure, and are often better served by advanced heart failure programs.

Knowing your type and class helps your doctor explain which evidence, if any, applies to you and what you can realistically expect.

What cell therapy may realistically offer

Based on current evidence, the most realistic expectations are:

  • Possible improvements in symptoms, exercise tolerance or quality of life in some patients.
  • Possible improvements in ejection fraction in some patients, as reported in small trials.
  • No guarantee of benefit, and no evidence that cell therapy allows patients to stop heart failure medications.
  • Continued need for cardiology follow-up, medications and lifestyle measures.
  • Objective measurement, with the same tests used before and after treatment, as the only reliable way to know whether anything changed.

Standard care saves lives

The European Society of Cardiology (ESC) heart failure guidelines describe treatments proven in large trials to reduce deaths and hospitalizations, especially for heart failure with reduced ejection fraction:

  • Medications: ACE inhibitors or angiotensin receptor-neprilysin inhibitors (ARNI), beta blockers, mineralocorticoid receptor antagonists and SGLT2 inhibitors, along with diuretics for congestion.
  • Devices: implantable cardioverter-defibrillators and cardiac resynchronization therapy for selected patients.
  • Procedures: revascularization, valve repair or replacement, and, in advanced cases, ventricular assist devices or heart transplantation.
  • Lifestyle and self-care: salt and fluid guidance, daily weight monitoring, physical activity and cardiac rehabilitation, vaccination and avoidance of alcohol and tobacco.

Stopping or reducing these treatments in favor of cell therapy can be dangerous. Any cell treatment should be added to, never substituted for, guideline-based care.

Know the warning signs

Whether or not you receive cell therapy, seek urgent medical care if you experience:

  • Sudden or severe shortness of breath, especially at rest or when lying down.
  • Chest pain or pressure.
  • Rapid weight gain (for example, more than 1 kg in a day or 2 kg in a week) or increasing leg swelling.
  • Fainting, a very fast or irregular heartbeat, or confusion.

How Stem Cell Mexico approaches CHF

  • Cells: allogeneic MSCs from Wharton's jelly of donated umbilical cords, obtained after healthy, full-term births with informed consent and donor screening. No autologous cells or other cell sources are used.
  • Laboratory: produced in a COFEPRIS-licensed laboratory under Good Manufacturing Practice standards, with quality and safety testing before release.
  • Evaluation: review of a recent echocardiogram, ECG, labs including kidney function and NT-proBNP when available, and your cardiologist's report.
  • Infusion: slow IV infusion with careful volume control and monitoring.
  • Follow-up: repeat tests at defined intervals, ideally with your cardiologist.

A COFEPRIS license authorizes the facility and laboratory to operate.

Warning signs when comparing clinics

Be cautious if a clinic promises to reverse heart failure, suggests stopping medications, uses testimonials instead of test results, says treatment is risk-free or does not request your echocardiogram and cardiology records.

What our patients usually receive

Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:

  • Wharton's jelly MSCs by IV infusion, usually between 100 and 200 million cells, depending on the condition, body weight and medical review.
  • One night at our facilities, sometimes two, with nursing and medical monitoring.
  • Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
  • Complementary therapies, such as PRP, exosomes or NAD+, only when the doctor considers them useful; they are always listed in your written plan.

Recovery is gradual, and each person responds differently. Some patients begin noticing changes within the first weeks, while others notice them over the following months, which is why our team stays in contact after treatment to follow your progress and decide whether a second application could help.

Questions to ask during your evaluation

  • What results are realistic for my type and stage of heart failure?
  • Is my medication plan fully optimized?
  • How will fluids and blood pressure be managed during treatment?
  • Which tests will measure change, and when?
  • How will you coordinate with my cardiologist?

Bottom line

Stem cell therapy does not cure congestive heart failure. Research shows mixed results, with some small trials reporting improvements in heart function and quality of life and the largest trial not meeting its main goal. At Stem Cell Mexico, Wharton's jelly MSCs are offered as a complement to proven heart failure care, with results that vary between individuals. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your heart condition, goals and medical history.

References

  1. Cochrane: Fisher SA et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure, 2016 (opens in a new tab)
  2. Perin EC et al. Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure (DREAM-HF). Journal of the American College of Cardiology, 2023 (opens in a new tab)
  3. Bartolucci J et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD trial). Circulation Research, 2017 (opens in a new tab)
  4. European Society of Cardiology (ESC): 2021 Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal (opens in a new tab)
  5. Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)

Request your medical evaluation

A clearer path starts here.

Tell us a little about yourself. We’ll help you understand the next step.

Vania, patient coordinator at Stem Cell Mexico

Vania, our patient coordinator

Your questions. Your travel plans.
A real person to help.

Talk to Vania on WhatsApp (opens in a new tab)

What happens next?

  1. Your advisor contacts you.
  2. We explain the medical review.
  3. You explore your options.

Call +1 800 646 0290

Let’s begin with you.

Your inquiry starts a conversation. Treatment requires medical evaluation.

Vania · Patient Advisor

Start my free evaluation
Free Consultation